Not that panic will suddenly break out here on August 15. It's supposed to be ...

https://www.tradingview.com/news/eqs:eff09478a094b:0-eckert-ziegler-implementation-of-the-share-split-by-issuing-bonus-shares-to-be-effective-on-15-august-2025/

$EUZ (-3,64%)

Hello everyone,

After more than a year, it's time to present my portfolio again, as a lot has changed.

I am clearly pursuing a buy-and-hold strategy with quality stocks. As a core I currently have the $GGRP (+0,11%)and the $IWDA (+0,21%) . The $GGRP (+0,11%) will soon leave my portfolio and half of it will be reallocated to the $IWDA and the $XDEM (+0,41%) will be reallocated. This is simply because I think it's a good idea to have an ETF in my more growth-oriented portfolio that doesn't just have dividend payers in its line-up.

I find the $XDEM (+0,41%) in particular, as it focuses exclusively on stocks that have performed well recently. The fact that the excess return naturally drives up volatility somewhat is perfectly okay, as my investment horizon is at least 20 years.

Otherwise, another 57% of my portfolio consists of individual shares. My plan has actually always been a 50/50 ratio, but this has changed somewhat due to the strong equity returns. However, the ETF positions will soon be filled with around 600 euros of my training income. This should then level out a little better, as long as shares don't continue to rise enormously.

If you take a closer look at the shares, I think the strong focus on the classic ETF drivers such as $NVDA (+1,04%) , $MSFT (+0,88%) , $GOOG (+0,86%) and $AMZN (+2,76%) stand out. Of course, the ETFs in the portfolio increase the proportion of these stocks, but that is absolutely intentional. I remain very optimistic about the AI runners and see further growth and sufficient stability in the coming years.

I always find the following particularly noteworthy $EUZ (-3,64%) . It is the only German company in my portfolio. I am very confident in the long term and am excited to see how they will develop. Unfortunately, my $MC (+0,03%) position should also be mentioned. Well, bad luck and I didn't have the courage to sell when the downward trend was clear. But at least I can now offset the taxes from the $GGRP (+0,11%)-sale by selling the LVMH position and then buying it again immediately. As soon as the luxury segment improves again, I am sure that LVMH will be back at the top of the industry.

The bottom part of my portfolio currently consists of $MCD (-0,11%) and $MDLZ (-0,27%) among others. Due to the strong returns of the other shares, these two positions have become somewhat unimportant in my portfolio. At around 2% each, they have simply become too small for me, which is why I will be merging them. However, not again in a stable share with a dividend, but rather in a growth driver. I am currently watching $ANET (-0,02%) and am pretty convinced. The restructuring will probably soon lead to a EUR 4,000 position in Arista and free up another EUR 2,000 for the ETFs.

That should be all. If you have any questions, please feel free to ask, otherwise I'm very happy to receive your feedback :)

(A little info: The sum of the deposit comes from my grandfather's inheritance. The ETF shares I bought early on were bought by my father, as I was of course too young. Then I got involved with shares and was allowed to have more and more of a say. I currently make my own decisions about the portfolio)

It is April 2020, and I am a young and hopeful student who has been studying the theory of financial education for several years and decide to take advantage of the supposedly unique opportunity of the "crash" to finally enter the stock market despite limited capital.

Theoretically, the idea was that it should be easy to get in during a difficult market phase, as all assets should be cheap due to the uncertainty. At least cheaper than they were before. When markets fall, multiples fall too. So even if you don't get everything right or even get a lot wrong, from a purely mathematical point of view you should still be better off than someone who got in in 2018 or 2019. So far, this logic is actually conclusive.

But the pandemic crash was not a normal crash. And I actually find it far too interesting not to talk about it.

In my experience, there is still a lot of talk today about the new markets in 2001 and the real estate bubble in 2008. However, the exciting market phase of the pandemic has hardly been looked back on at all. This may also be due to the fact that we don't feel we can look back at it yet, as we can still feel the effects and have barely really overcome them. However, it is now slowly becoming apparent that a new era has dawned on the market, which is primarily about tariffs, trade deficits and currencies.

But what makes the pandemic a bad time to start?

If you look back at the charts of some securities (and for the sake of clarity, I would like to refer mainly to equities here), you can see several things.

In the case of shares with a gravitas such as $BRK.B (-0,18%) only a tiny corona dent can be seen on the long-term chart. From this you can see that it didn't really matter when you invested. However, the earlier the better. It was important to invest at all, but it was not necessary to wait for a specific point in time. However, this even applies to clear pandemic losers such as $BKNG (+0,62%) and $EVD (+0,33%) .

For some stocks like $AMZN (+2,76%) and $MSFT (+0,88%) the entry point during the actual crash was not ideal. There was an optimal entry point for both stocks recently, but this would not have been apparent until 2-3 years after the crash. Both stocks survived the pandemic almost unscathed, but were then affected by severe secondary factors that put the business under pressure.

Stocks like $TMO (-0,27%) or $AFX (+1,46%) were considered pandemic winners. You could have picked them up at the beginning of the crash ... or you could have left them alone and got them back 5 years later at exactly the same price as before the pandemic started.

And now the worst category: hype stocks. The absolute catastrophe happened to all those who were looking for opportunities where there were actually none. Whether investments in emerging markets or hopes for the future in $ZM (-0,41%) and $FVRR (-0,93%) - Money that was taken out of the broad market ended up largely concentrated in assets that will not reach their ATH for another 20 years. Anyone wanting to be in it for the long term found their Waterloo in the pandemic. Some companies such as $EUZ (-3,64%) or $SRT (-0,37%) may well be doing great things. But here the "crash" was simply the absolute worst entry opportunity of the entire decade.

Correction Edit: I only found a group of stocks that I really needed to buy in the crash and that was Big Oil. There were certainly other stocks that were a bit cheaper at the time. But for the most part, it was not essential to enter at the low point in order to make good returns. That is what made this market phase so difficult. The good stocks were NOT extremely cheap, but there were many bad stocks that were extremely expensive. For newcomers, such a situation is incredibly difficult to navigate.

I closed 2020 with +12% and 2021 with +8% only to get a -22% in 2022. So I didn't make any returns at all in the first 3 years and just paid a lesson.

I thought I would have been smart at least not to have entered in 2018/2019 when all shares were valued much higher on average. But I might have gained experience in these two years so that I would have had more guidance in 2020. Or I could have started in 2022/2023, when there were no more hype stocks and you could pour money into the market with a watering can and it almost always turned into a flower.

I recently saw the portfolio of a friend who restarted his portfolio in 2022. Almost the same portfolio size as mine. However, while I have made 7% p.a. since the start of my portfolio, he has an IZF of 15%. With a portfolio size of 100k, this means that I am sitting on €12,000 book profits and he on €33,000

Backtests are currently showing that my strategy has really put me to sleep and put me to sleep by ALL known and common indices over 5 years. The only consolation here is really the 3-year performance, where it is clear that I can keep up with the major indices and also leave a few big names behind me.

So on a positive note: I'm getting better.

$EUZ (-3,64%)

Eckert & Ziegler

From the high of Eur 141.40 in 2021

to the low 3 years later at Eur 28.92

Minus 80 % 😑

Buy into rising prices, outperform the market.

The current upward trend is intact and resolved an upward consolidation lasting several days.

Volume was high, buy volume on rising prices is positive.

Currently a 3 year high. Stop 🛑 zones at 59 euros for a positive trend.

Congratulations to all those who bought from 2022.

With even? Waiting for zero return after 4 years.

Since small caps have only been running again since 2024, the return is negative for the years before that.

• Eckert & Ziegler SE recorded sales growth to € 68.2 million in the first quarter of 2025 compared to € 67.6 million in the previous year.
• EBIT before special items rose by 8% to € 16.2 million, while net profit increased by 14% to € 9.7 million.
• Despite a cyberattack and a short-term delivery stop for gallium generators, the company was able to confirm its annual forecast for 2025 with sales of around € 320 million and EBIT of around € 78 million.
• Sales in the Medical segment remained stable at € 34.4 million, with pharmaceutical radioisotopes being the most important revenue driver.
• The Isotope Products segment achieved a slight increase in sales of 2% to € 33.8 million.

Eckert & Ziegler SE is a leading provider of isotope technology components for nuclear medicine and radiotherapy and is listed on the TecDAX of the German Stock Exchange.

https://www.ezag.com/wp-content/uploads/2025/05/EZAG_Q1-2025.pdf

$EUZ (-3,64%)

Good evening,

I would be interested to know which shares you can recommend from medium-sized companies with a medium investment horizon (approx. 1 year)!

Constructive discussions are also welcome werden☮️.

I'll throw something straight into the round:

$EUZ (-3,64%) stable with healthy growth (I've already posted this today🤫)

Hi, my name is Max, I'm 18 years old and I'm interested in social media and the stock market.

That's exactly why I'd like to document my financial career on Getquin from now on and talk about it with you. As you can probably tell from the name, my goal is to retire at the age of 50. I would like to make this possible through my share portfolio. Thanks to an inheritance, I had the opportunity to skip the hard road to the first €100,000. However, as I was only 15 years old at the time I found out about the inheritance, I had a lot to learn first. Now I'm 18 years old and already know a bit more. Over time, the stock market has become my hobby and hardly a day goes by when I don't spend time with it.

How it all began

As already mentioned, my interest in the stock market was triggered by the inheritance I received in 2019. Since the deceased relative also had a great interest in the stock market and had invested very successfully for many years, my father thought it would certainly be in his interest if I invested the money too. Fortunately, my father is also very experienced in the stock market, so he was able to explain a lot to me. So it wasn't long before I bought my first ETF with him. This was classically the $IWDA (+0,21%) . I also bought a fund for the Asian region $JQ8Y72 . At the time, this was a recommendation from a friend's bank. However, I sold this fund at some point with a loss of around 25%. That wasn't the best start, of course, but it did teach me how to deal with losses. In those early days, I learned a lot about the stock market from YouTube, but also from other platforms such as Der Aktionär and Finanzen100.

The first individual shares were added in 2023. That was back then $GOOGL (+1,02%) and $DHL (-0,54%) . This was followed by other tech giants such as $AMZN (+2,76%) , $MSFT (+0,88%) and $AAPL (-0,15%) . I now have 17 different individual stocks. Looking at my portfolio, most of them will probably be familiar to you, but there are also some smaller stocks like $EUZ (-3,64%) , $NHH (+0,15%) and $LNN (-1,35%) I bought because I find them exciting for the future.

Past and future

Fortunately, my portfolio has performed really well in recent years, in my opinion. This year, too, I am going into the new year with around 20%. Tech stocks in particular have performed strongly and generated decent returns. As I am very optimistic about the tech giants for the next few years, I will continue to hold them in my ETFs despite the doubling. As things stand today, however, I have 2 positions that I would like to change. $DHL (-0,54%) will probably be the first stock to leave my portfolio. Personally, I just don't have the feeling that the company is developing as strongly as many of my other shares. Of course the DHL share is great as a dividend stock, but I want to focus on growth first. That's exactly why I'm going to $GGRP (+0,11%) reallocation. The current replacement is the $FUSD (+0,48%) . I like the quality focus behind these ETFs, but I don't need GGRP's shifted focus on dividend stocks, as I don't really care about dividends at the moment.

In September 2025, I will start my apprenticeship as a bank clerk. From then on, I plan to finally set up my first savings plan. As I'll still be living at home at this point, it should be easy to save a high proportion of my trainee salary. But I'm also making sure that it's not too high - after all, I don't want my quality of life to suffer because of my savings.

Building up additional income

I have been very interested in social media since 2020. When I was 14 years old, I started an Instagram page and reached over 25,000 subscribers within 1-2 years. During this time, I was doing really well financially and I experienced some really great things. For example, I raffled off 120 liters of beer to my community with a brewery. But I'll write a post about that in my subscriber feed soon. After all, the whole thing doesn't really have anything to do with the stock market, which is why I don't want to burden the homepage with it. However, if any of you are still interested, feel free to follow me and read the story soon.

There I will also explain again why I can no longer use the site.

I'm currently trying my hand at YouTube. I'm using artificial intelligence to create videos in the hotel niche. The results are surprisingly good. More on that soon ;)

I'm also currently trying to build up my reach on Instagram. I recently opened an account on Instagram, which should address the same topics as this Getquin account. If you are interested, you are of course welcome to drop by. I'll try to add the link to the account here:

Generation Aktienrente 📈| Vermögensaufbau mit 18 (@aktienrente.mit.50) • Instagram-Fotos und -Videos

With the help of these projects, I hope to be able to build up a more or less passive income in the future, which I can then put directly into my share portfolio. However, to be honest, I also enjoy them as they are, which is why an additional income is not absolutely necessary.

Nevertheless, I will upload regular updates to my feed, which will document my current projects and their developments in detail.

End

This brings us to the end of my first article. I hope I have been able to arouse the interest of at least a few of you and would of course be delighted to receive feedback and suggestions for improving my portfolio and my plans.

I wish you all a happy new year!

Analyst updates, 28.11.

⬆️⬆️⬆️

- HAUCK AUFHÄUSER IB raises the price target for ECKERT & ZIEGLER from EUR 55 to EUR 56.50. Buy. $EUZ (-3,64%)

- EXANE BNP raises the target price for FREENET from EUR 30 to EUR 34. Outperform. $FNTN (-0,35%)

- HAUCK AUFHÄUSER IB raises the price target for NORTHERN DATA from EUR 45 to EUR 52. Buy. $NB2 (-3,12%)

- WARBURG RESEARCH raises the price target for PATRIZIA from EUR 9.80 to EUR 9.90. Buy. $PAT (+0,13%)

- DEUTSCHE BANK RESEARCH raises the price target for EASYJET from GBP 6.70 to GBP 7.15. Buy. $EZJ (+0,66%)

- EXANE BNP upgrades TRATON to Outperform. Target price EUR 35. $8TRA (+0,53%)

- JPMORGAN raises the price target for CTS EVENTIM from EUR 101 to EUR 104. Overweight. $EVD (+0,33%)

⬇️⬇️⬇️

- BRYAN GARNIER lowers the price target for LVMH from EUR 800 to EUR 770. Buy. $MC (+0,03%)

- KEPLER CHEUVREUX lowers the price target for PORSCHE SE from EUR 48 to EUR 47. Buy. $PAH3 (-1,05%)

- DEUTSCHE BANK RESEARCH lowers the price target for SYMRISE from EUR 130 to EUR 125. Buy. $SY1 (+0,06%)

- WARBURG RESEARCH lowers the price target for ABO ENERGY from EUR 114 to EUR 110. Buy. $AB9 (-0,89%)

- EXANE BNP lowers the target price for 1&1 from EUR 15 to EUR 12. Neutral. $1U1 (-0,48%)

- EXANE BNP lowers the price target for UNITED INTERNET from EUR 20 to EUR 17. Neutral. $UTDI (-0,36%)

- STIFEL downgrades COMPUGROUP from Buy to Hold and lowers target price from EUR 64 to EUR 18. $COP (-0,42%)

- BARCLAYS lowers the price target for SCHOTT PHARMA from EUR 33 to EUR 27. Equal-Weight. $1SXP (+0,54%)

- UBS lowers the price target for VESTAS from DKK 245 to DKK 175. Buy. $VWS (-1,94%)

Analyst updates, 25.11.

⬆️⬆️⬆️

- MORGAN STANLEY upgrades ROBINHOOD to Overweight. Target price USD 55. $HOOD (+0,21%)

- BARCLAYS raises the price target for DEUTSCHE TELEKOM from EUR 37 to EUR 39.50. Overweight. $DTE (+1,07%)

- BERENBERG raises the target price for SIEMENS ENERGY from EUR 35 to EUR 70. Buy. $ENR (-1,39%)

- UBS raises the target price for RHEINMETALL from EUR 570 to EUR 630. Neutral. $RHM (+3,04%)

- BARCLAYS raises the price target for 1&1 from EUR 17 to EUR 20. Equal-Weight. $1U1 (-0,48%)

- DEUTSCHE BANK RESEARCH upgrades VESTAS from Hold to Buy. $VWS (-1,94%)

- DEUTSCHE BANK RESEARCH raises the price target for VONOVIA from EUR 33 to EUR 38. Buy. $VNA (+1,51%)

- DEUTSCHE BANK RESEARCH raises the price target for TAG IMMOBILIEN from EUR 16 to EUR 18. Buy. $TEG (+2,06%)

- DEUTSCHE BANK RESEARCH upgrades AROUNDTOWN from Sell to Hold. Target price EUR 2.80. $AT1 (+2,33%)

- DEUTSCHE BANK RESEARCH raises the price target for LEG IMMOBILIEN from EUR 90 to EUR 105. Buy. $LEG (+1,91%)

- DEUTSCHE BANK RESEARCH upgrades DEUTSCHE WOHNEN from Hold to Buy and raises target price from EUR 19 to EUR 28. $DWNI (+0,98%)

- STIFEL raises the price target for NOVARTIS from CHF 106 to CHF 109. Hold. $NUVN

- DEUTSCHE BANK RESEARCH upgrades JD SPORTS FASHION from Sell to Hold. $JD. (-0,98%)

- DEUTSCHE BANK RESEARCH raises the price target for ALSTOM from EUR 22 to EUR 25. Buy. $ALO (+0,42%)

- MORGAN STANLEY raises the price target for DEUTSCHE BÖRSE from EUR 213 to EUR 232. Equal-Weight. $DB1 (+1,18%)

- KEPLER CHEUVREUX raises the target price for ECKERT & ZIEGLER from 57.30 EUR to 60.30 EUR. Buy. $EUZ (-3,64%)

- BARCLAYS raises the target price for UNITED INTERNET from EUR 23 to EUR 26. Equal-Weight. $UTDI (-0,36%)

- JEFFERIES raises the price target for HEIDELBERG MATERIALS from 142.10 EUR to 145.50 EUR. Buy. $HEI (+0,7%)

⬇️⬇️⬇️

- DEUTSCHE BANK RESEARCH lowers the price target for KION from EUR 55 to EUR 50. Buy. $KGX (+2,12%)

- DEUTSCHE BANK RESEARCH lowers the price target for CTS EVENTIM from EUR 114 to EUR 106. Buy. $EVD (+0,33%)

- GOLDMAN downgrades ORSTED from Buy to Neutral and lowers target price from DKK 520 to DKK 445. $ORSTED (-2,59%)

- DEUTSCHE BANK RESEARCH lowers the price target for H&M from SEK 200 to SEK 190. Buy. $HM B (-1,54%)

- MORGAN STANLEY lowers the price target for MERCK KGAA from EUR 200 to EUR 190. Overweight. $MRK (+0,92%)

- BARCLAYS lowers the target price for THYSSENKRUPP from EUR 4.40 to EUR 4. Underweight. $TKA (-8,69%)

- MORGAN STANLEY downgrades ING to Equal-Weight. Target price EUR 17.50. $ING (+0,95%)

- JPMORGAN lowers target price for RWE from EUR 48 to EUR 47.50. Overweight. $RWE (-3,82%)

Eckert Ziegler Q3 2024 $EUZ (-3,64%)

Financial performance:

• Sales growth: Sales increased by 17% to € 215.5 million (previous year: € 183.9 million), indicating strong demand, particularly in the medical sector.
• Net income: Net income increased by 15% to 23.4 million euros, reflecting a positive earnings trend.
• EBIT: EBIT before special effects increased by 9.0 million euros to 46.7 million euros, indicating improved operating efficiency.

Balance sheet overview:

• Total assets: Increase to 481 million euros (previous year: 439 million euros), indicating growth and increased investments.
• Equity: Increase of 26.2 million euros to 250.3 million euros.
• Liabilities: Loan liabilities fell by 4.8 million euros to 21.5 million euros, reducing the debt burden.

Details of the profit and loss account:

• Gross profit: Increased to 106.9 million euros (previous year: 89.8 million euros), due to margin improvements and sales growth.
• Cost of sales: Slight increase to 19.8 million euros (previous year: 18.8 million euros).
• General and administrative expenses: Increased to 33.4 million euros (previous year: 28.9 million euros), possibly due to investments in the corporate structure.

Cash flow overview:

• Operating cash flow: Significant increase to 45.1 million euros (previous year: 17.5 million euros), indicating strong cash management.
• Investing activities: Cash outflow reduced to 1.4 million euros (previous year: 19.8 million euros), indicating a more cautious investment policy.
• Financing activities: Outflow of 15.9 million euros, possibly for debt repayment or dividends.

Key figures and profitability metrics:

• Equity ratio: 52%, showing a solid capital base.
• Earnings per share (EPS): Increased to 1.12 euros (previous year: 0.98 euros), adding value for shareholders.

Segment information:

• Medical segment: External sales increased by 26% to 104.5 million euros, driven by demand in the pharmaceutical radioisotope segment.
• Isotope Products segment: Sales increased by 10 % to 111.0 million euros, indicating stable growth in this segment.

Competitive position: The company demonstrates a strong market position in the medical segment, particularly in the area of radioisotopes for pharmaceutical applications, which represents a significant growth area.

Forecasts and management commentary: The management plans to use excess liquidity to finance new projects in the medical segment, which will enable further growth in a segment with high potential.

Risks and opportunities:

• Currency effects: Positive impact on the Group result by 0.4 million euros.
• Discontinued operations: Losses from wound-up business increased from 3.1 million euros to 5.9 million euros, which could have a negative impact on profitability.

Summary of results:

Positive aspects:

• Sales growth: Solid growth of 17%.
• Increased profitability: Net profit increase of 15% and increase in operational efficiency.
• Strong segment growth: The medical segment recorded a 26% increase in sales.
• Improved operating cash flow: Strong cash generation for future investments.
• Stronger equity and reduced debt: Increased financial stability.

Negative aspects:

• Losses from discontinued operations: Increased loss from discontinued operations negatively impacts earnings.
• Higher administrative costs: Possible reduction in efficiency due to increased general costs.
• Slight increase in selling costs: Could put slight pressure on margins.
• Cash outflow from financing activities: Potentially a constraint on investment flexibility.
• Write-downs and depreciation in the "Other" segment: Burden on profitability.